Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 241 to 250 of 1090 total matches.
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
infants whose mothers were taking
codeine
Drug Interactions
Concurrent use of other CNS depressants ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Prasugrel (Effient) vs. Clopidogrel (Plavix)
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009 (Issue 1320)
INTERACTIONS — Use of nonsteroidal antiinflammatory drugs (NSAIDs), other antiplatelet drugs ...
The FDA has approved prasugrel (Effient - Lilly/Daiichi Sankyo), an oral antiplatelet drug, for use with aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndromes (ACS) being managed with percutaneous coronary intervention (PCI). It will compete with clopidogrel (Plavix) for such use.
Vibegron (Gemtesa) for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
has
been detected in the milk of lactating rats administered
radiolabeled vibegron.
DRUG INTERACTIONS — Taking ...
The FDA has approved the selective beta-3 adrenergic
agonist vibegron (Gemtesa – Urovant Sciences)
for treatment of overactive bladder in adults with
symptoms of urge urinary incontinence, urgency, and
urinary frequency. It is the second beta-3 agonist to
be approved in the US; mirabegron (Myrbetriq) was
the first.
Telbivudine (Tyzeka) for Chronic Hepatitis B
The Medical Letter on Drugs and Therapeutics • Jan 29, 2007 (Issue 1253)
and is classified by the FDA
as category B for use during pregnancy.
DRUG INTERACTIONS — No drug interactions ...
The FDA has approved the nucleoside analog telbivudine (Tyzeka - Novartis/Idenix) for treatment of patients ≥16 years old with active chronic hepatitis B virus (HBV) infection. It is the fourth oral drug marketed for this indication in the US.
Tipranavir (Aptivus) for HIV
The Medical Letter on Drugs and Therapeutics • Oct 10, 2005 (Issue 1219)
allergy.
DRUG INTERACTIONS — The combination of tipranavir
with ritonavir is a net inhibitor of CYP3A ...
Tipranavir (Aptivus - Boehringer Ingelheim), a new protease inhibitor, has received accelerated approval from the FDA. It must be given with ritonavir (Norvir). The combination is indicated for use with other antiretrovirals to treat HIV infection in highly treatment-experienced adults who have ongoing viral replication or in those with HIV strains known to be resistant to multiple protease inhibitors.
Tetrabenazine (Xenazine) for Huntington's Chorea
The Medical Letter on Drugs and Therapeutics • Jan 26, 2009 (Issue 1304)
(in Italian, French, Spanish and Japanese), a second
newsletter (Treatment Guidelines), a drug interactions ...
Tetrabenazine (Xenazine - Ovation Pharmaceuticals), an old drug first synthesized 50 years ago for treatment of schizophrenia, was recently approved by the FDA for the treatment of chorea associated with Huntington's disease. It has been available in other countries for decades.
Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria
The Medical Letter on Drugs and Therapeutics • Sep 24, 2007 (Issue 1270)
: Jean-Marie Pflomm, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D ...
Eculizumab (Soliris - Alexion) has been approved by the FDA for reduction of hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare form of hemolytic anemia. A recombinant humanized monoclonal antibody, eculizumab is the first drug to be marketed for this indication.
ThermaClear for Acne
The Medical Letter on Drugs and Therapeutics • Jun 18, 2007 (Issue 1263)
, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D., University of Washington ...
The FDA has approved ThermaClear (Therative), a battery-powered, handheld device, to treat individual acne lesions with heat. ThermaClear is indicated only for use on mild to moderate inflammatory acne, not severe nodular or severe cystic acne, and it is not meant to be used on blackheads and whiteheads. Two similar devices are already on the market: Zeno, another handheld device that delivers heat to acne lesions, and the Radiancy Clear Touch Lite Acne Clearance System, a larger heat-delivery device.
Dasatinib (Sprycel) for CML and Ph+ ALL
The Medical Letter on Drugs and Therapeutics • Jan 15, 2007 (Issue 1252)
effusion occurred more frequently
in dasatinib-treated patients.
DRUG INTERACTIONS — Dasatinib ...
Dasatinib (Sprycel - Bristol-Myers Squibb), an inhibitor of multiple tyrosine kinases, has been approved by the FDA for second-line treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults.
Reducing Intake of Trans Fatty Acids
The Medical Letter on Drugs and Therapeutics • Aug 13, 2007 (Issue 1267)
, DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D ...
...